Q2 Earnings Forecast for Liquidia Issued By HC Wainwright

Liquidia Co. (NASDAQ:LQDA) – Research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Liquidia in a report issued on Thursday, March 20th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.46) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.25) EPS and FY2029 earnings at $0.51 EPS.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million.

Several other equities analysts have also recently weighed in on the stock. Wells Fargo & Company began coverage on shares of Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company. Needham & Company LLC raised their price target on shares of Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Scotiabank raised their price target on shares of Liquidia from $30.00 to $34.00 and gave the stock a “sector outperform” rating in a research note on Thursday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $26.63.

Liquidia Stock Performance

NASDAQ LQDA opened at $15.12 on Friday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -9.28 and a beta of 0.07. Liquidia has a 52-week low of $8.26 and a 52-week high of $16.92. The business has a 50 day simple moving average of $14.79 and a 200 day simple moving average of $12.20.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently added to or reduced their stakes in LQDA. Steward Partners Investment Advisory LLC acquired a new stake in shares of Liquidia during the fourth quarter worth $59,000. Summit Investment Advisors Inc. lifted its holdings in shares of Liquidia by 35.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after buying an additional 1,719 shares in the last quarter. Walleye Trading LLC lifted its holdings in shares of Liquidia by 54.7% during the third quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock worth $132,000 after buying an additional 4,670 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new stake in shares of Liquidia during the fourth quarter worth $142,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Liquidia during the fourth quarter worth $154,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Buying and Selling at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 23,370 shares of the firm’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now owns 401,755 shares of the company’s stock, valued at $4,732,673.90. This trade represents a 5.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Rajeev Saggar sold 6,249 shares of the firm’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $73,613.22. Following the sale, the insider now directly owns 270,388 shares of the company’s stock, valued at $3,185,170.64. This represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,245 shares of company stock valued at $843,326 in the last quarter. 30.10% of the stock is currently owned by insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).